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The 18F-FDG uptake pattern on PET could be an indicator of the
prognosis and aggressiveness of various tumors, including he-
patocellular carcinoma (HCC). Hexokinase, especially hexoki-
nase type II (HKII), plays a critical role in 18F-FDG uptake in
rapidly growing tumors. We established a stable cell line overex-
pressing HKII by the transfection of full DNA of HKII to HCC cells
(SNU449) that express low levels of HKII and investigated how
18F-FDG uptake mechanisms, especially overexpression of
HKII, are linked to tumor proliferation mechanisms. Methods:
The HKII gene was stably transfected to SNU449 cells with an
expression vector. HKII expression in the cells was verified by
reverse-transcriptase polymerase chain reaction, Western blot
analysis, adenosine triphosphate (ATP) and lactate production,
18F-FDG uptake measurement, and confocal microscopy. Cellu-
lar proliferation activity and response to the anticancer drug
cisplatin were evaluated by cell counting using 3-(4,5-dimeth-
ylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. For the
evaluation of molecular pathways involved in tumor proliferation,
the phosphatidylinositol 3-kinase (PI3K)/Akt pathway was inves-
tigated. Results: The stable cell line produced HKII effectively,
but expression of other enzymes or transporters for glycolysis,
such as glucose-6-phosphatase (G6Pase), HKI and III, and glu-
cose transporter type 1 and 2 (Glut-1 and Glut-2), did not show
any changes. 18F-FDG uptake was significantly increased after
transfection. ATP and lactate production was also increased af-
ter transfection. Overexpressed HKII was associated with mito-
chondria on confocal microscopy. Cells with overexpression of
HKII, compared with the nontransfected cell line, showed 1.5-
to 2-fold higher cell survival and resistance to the anticancer
agent cisplatin (2- to 8-fold). In themolecular study, the activated
form of Akt was increased after transfection, and PI3K inhibitor
dissociated the mitochondrial HKII to the cytoplasm. In addition,
the adenosinemonophosphate–activated protein kinase (AMPK)
pathway is also involved in Akt signaling.Conclusion:HKII plays
an important role in 18F-FDG uptake and tumor proliferation by
both the PI3K-dependent and the PI3K-independent Akt signal
pathways; therefore, the 18F-FDG uptake pattern on a PET
scan can be a surrogate marker of prognosis in HCC.
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Because of its high sensitivity and specificity in the
diagnosis and staging of various cancers or detection of
recurrent tumors after treatment, 18F-FDG PET is widely
used in the oncology field (1). As cancer cell growth depends
on glucose metabolism as a major energy substrate, in-
creased 18F-FDG uptake on PET scans is known to be an
indicator of the poor prognosis and aggressiveness of
various tumors (2,3). The main mechanisms of 18F-FDG
uptake in tumor cells are increased expression of the
facilitated glucose transporters including type 1 (Glut-1) on
the cell membrane and rate-limiting glycolytic enzymes,
especially hexokinase type II (HKII) (4). It has been
reported that well-differentiated hepatocellular carcinoma
(HCC) shows low 18F-FDG uptake, but poorly differenti-
ated HCC shows increased HKII expression and, subse-
quently, increased 18F-FDG uptake (5).
In the early 1930s, Dr. Otto Warburg reported that tumor
cells have high glycolytic rates despite high oxygen con-
centration, which is known as the Warburg effect (6).
Tumor cells use more glucose than normal cells through
insufficient energy metabolism by producing lactate instead
of using oxidative phosphorylation (7,8). As tumor cells
with uncontrolled cell growth need more energy, the
essential enzyme hexokinase is overexpressed to maintain
high glycolytic activity (9,10). In particular, most malig-
nant cells express HKII instead of HKI (7), especially the
mitochondrially bound form (11). Mitochondria-bound
hexokinases have the advantage of using adenosine triphos-
phate (ATP) produced by oxidative phosphorylation in the
mitochondria as the substrate to phosphorylate incoming
glucose (12,13). Furthermore, hexokinase binds to the outer
mitochondrial membrane at sites where the voltage-depen-
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dent anion channel (VDAC) is located (14). The VDACs
are in close association with the adenine nucleotide trans-
locator (ANT), which facilitates the exchange of cytoplas-
mic adenosine diphosphate for mitochondrial ATP (15).
Recently, it has been reported that the VDAC-ANT
complex plays an important role in regulating mitochon-
drial permeability transition and release of apoptotic factors
such as cytochrome c (15,16). V-akt murine thymoma viral
oncogene (Akt), known as a protein kinase B, mediates
translocation of cytosolic HKII to the mitochondrial outer
membrane for producing a VDAC-ANT-HKII complex that
prevents cytochrome c release and apoptosis. From the
clinical aspect, poorly differentiated HCC expresses HKII
much higher than low-grade HCC, although Glut-1 expres-
sion is not always increased (5,17,18). Those poorly
differentiated HCCs show high uptake of 18F-FDG on the
18F-FDG PET scan and poor survival (2,3). Therefore,
HKII appears to play an important role in maintaining
malignancy in tumor cells with poor survival, but molecular
mechanisms, especially the relationship between 18F-FDG
uptake mechanisms with regard to tumor progression, have
not yet been well investigated.
In this study, we transfected full-length DNA of HKII
into the SNU449 human HCC cell line that shows low HKII
expression and investigated the role of HKII in 18F-FDG
uptake with regard to the molecular mechanisms of the
cellular proliferation, antiapoptotic effect, and chemother-
apeutic response. This experimental study could provide
biologic evidence of increased 18F-FDG uptake on the PET
scan as a surrogate marker of poor prognosis in HCC.
MATERIALS AND METHODS
Materials
DEAE-Sepharose Fast Flow, CM-Sepharose Fast Flow, and
Sephacryl S-200 High Resolution were purchased from Amer-
sham Biosciences, and Ni-NTA resin, b-D-thiogalactopyrano-
side (IPTG), cisplatin, 4-(2-hydroxyethyl)-1-piperazineethane
sulfanic acid (HEPES) buffer, and dithioerythritol were pur-
chased from Sigma. Leupeptin, pepstatin, phenylmethanesulpho-
nylfluoride (PMSF), and imidazole were purchased from
Boehringer Manheim. Glucose, Leuconostoc mesentroides glu-
cose-6-phosphate dehydrogenase (G6PD), and ATP (disodium
salt) were obtained from Roche Chemical Co. Nicotinamide
adenine dinucleotide (NAD1, disodium salt) was purchased from
Fluka Chemical Co.
Cell Culture and Gene Expression Profile of HKII
SNU449 and SNU-475 human HCC cell lines were obtained
from the Korean Cell Line Bank and grown in RPMI 1640
supplemented with 10% heat-inactivated fetal bovine serum,
penicillin (100 U/mL), and streptomycin (100 mg/mL). Control
hepatocytes (Chang cells), HepG2, and Hep3B human HCC cell
lines obtained from the American Type Culture Collection were
maintained in Dulbecco’s modified Eagle’s medium supplemented
with 10% fetal bovine serum and penicillin–streptomycin (100
U/mL) in a humidified atmosphere of 95% air and 5% CO2 at
37C. We evaluated HKII expression in those cell lines. As shown
in Supplemental Figure 1, HepG2 or Hep3B and SNU-475 cells
showed high expression of HKII, whereas SNU449 cells showed
significantly lower expression, compared with other cell lines.
Construction of Expression Vectors for HKII
The protein coding regions of the full-length of HKII were
amplified by polymerase chain reaction (PCR) with a 59-oligonu-
cleotide primer CGAGCTCCATATGA TTGCCTCGCATCTGCT
and the 39-oligonucleotide primers CGGAATTCTTAATGA
TGATGATGATGTCGCTGTCCAGCCT containing the restric-
tion enzyme sites underlined above, respectively. The amplified
DNAs were gel-purified, digested with appropriate enzymes, and
then ligated into the pRSET A bacterial expression vector
(Invitrogen) that had been digested with the appropriate restriction
enzymes. All constructs were confirmed by DNA sequencing. To
generate mammalian expression plasmid DNA, the HKII construct
was isolated from pRSET A by a Nde I/Klenow and EcoR I
treatment and then ligated into pcDNA 3.1/Myc-His (Invitrogen)
treated with EcoR V and EcoR I. The construct was confirmed by
DNA sequencing.
Bacterial Expression and Purification of Recombinant
HKII Proteins
The rhHKII was overexpressed in Escherichia coli (BL21), and
the recombinant proteins were purified to apparent homogeneity.
The proteins were purified by Ni-NTA resin according to the
manufacturer’s instruction (Sigma). The proteins were concen-
trated and buffer-changed with a Centricon apparatus (Amicon).
The proteins were measured with the bicinchoninic acid (BCA)
assay and stored at 270C.
Establishment of Stable Cell Lines Expressing HKII in
HCC Cells
To investigate whether HKII overexpression induces rapid cell
growth, proliferation, and antiapoptotic effect in tumor cells, we
transfected HKII into the HCC cell line SNU449 (low expression
of HKII) and Chang cells (normal hepatic cell line). To obtain
stable HKII-expressing cell lines, we plated SNU449 and Chang
cells at a density of 150,000 cells/60-mm dish 20 h before
transfection. For transfection, lipofectamine (15 mL) with 4 mg
of plasmid DNA was added, and the cells were incubated at 37C
for 4 h and washed once with serum-free RPMI 1640. After 14–20
d of selection in medium containing 1 mg of Geneticin (G418;
Invitrogen) per milliliter, resistant colonies were isolated with
cloning rings and transferred to separate culture dishes for
expansion. After transfection of the HKII gene, in the case of
SNU449-HKII cells the RNA level was much higher than that in
nontransfected SNU449 cells and was similar to that of HepG2
HKII, which was a positive control. Additionally, after transfec-
tion of HKII into Chang cells, we could confirm the elevation of
HKII level in Chang cells. These results showed similar patterns in
protein level (Fig. 1).
18F-FDG Uptake Study
For radiotracer uptake measurement, 5 · 104 cells were seeded
in a cavity of a 24-well plate (Greiner) and cultured in a
humidified atmosphere of 5% CO2 at 37C using the above-
mentioned cell culture medium. 18F-FDG uptake was determined
on confluent cells by incubation of the cells for 30 min at 37C
with fresh medium containing 185 kBq (5 mCi) of 18F-FDG/mL.
Cells were washed 5 times with 5 mL of ice-cold phosphate-
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buffered saline (PBS). Images were obtained on a PET scanner
(Allegro; Philips-ADAC Medical Systems). An emission scan of 3
min was taken on the 12-well plates. A transmission scan (4 s) was
immediately obtained using low-dose CT to correct for attenuation
correction. The images were reconstructed using a row-action
maximal likelihood algorithm for the Allegro system. Subse-
quently, cells were washed 5 times with ice-cold PBS and lysed in
0.5 mL of 0.1 M sodium hydroxide with 1% sodium dodecyl
sulfate (SDS). Cell lysates were counted with a Cobra II g-counter
(Canberra-Packard). Protein levels were quantified using the BCA
protein assay kit (Pierce) according to the manufacturer’s recom-
mendations and bovine serum albumin (BSA) as protein standard.
Immunofluorescence Assay of HKII Using
Confocal Microscopy
For confocal microscopic analysis, cells were seeded at 5 · 104
cells in a Laboratory-Tek German borosilicate cover glass with 8
chambers (Nunc; Nagel Inc.) and grown for 24 h in complete
medium. Subsequently, cells were washed and preincubated in
200 mL of RPMI. After incubation at 37C for 30 min, cells were
fixed with 2% glutaraldehyde and 2% formaldehyde in PBS for 15
min at 37C. Cells then were washed with PBS containing 10 mM
ethylenediaminetetraacetic acid (EDTA), permeabilized with
methanol for 10 min at 220C, and washed 3 times with PBS
containing 10 mM EDTA. Cells were blocked for 1 h with PBS
containing 5% BSA. After that, cells were incubated with the
primary antibody (anti-HKII, 1:250 dilution) at 4C overnight,
rinsed 3 times with PBS, blocked again for 15 min with PBS
containing 5% BSA, incubated with the secondary antibody
(Alexa 594 goat-antimouse, 1:2,000 dilution) at room temperature
for 2 h, and then rinsed 3 times with PBS. Subsequently Mito
Tracker Green FM (Molecular Probes) staining was performed as
follows: Cells were washed once with PBS and then 0.1 M Tris/
NaCl buffer, pH 8.0, containing 0.05% BSA and were incubated
with 100 nM Mito Tracker Green FM for 15 min at 37C in the
dark in an atmosphere of 5% CO2. Cells were further washed and
placed in ice-cold PBS. Photographs were taken with a Zeiss
model LSM510 invert on the base of an Axiovert 100 microscope
(Carl Zeiss B.V.).
Total RNA Preparation and Reverse-Transcriptase
Polymerase Chain Reaction (RT-PCR)
An RNeasy kit (Qiagen) was used to extract total RNA from
each sample of 2 · 106 cells. The Superscript II RT-PCR kit
(Invitrogen) was used to generate cDNA from the total RNA
isolated from each of the cell lines. The final cDNA of Glut-1–3,
HKI–III, G6Pase, and glyceraldehyde-3-phosphate dehydrogenase
was then determined with a spectrophotometer. PCR was per-
formed for 35 cycles (94C for 40 s, 55C for 40 s, and 72C for
60 s per cycle) in a reaction mixture consisting of 5 mL of 10·
PCR buffer (100 mM Tris-HCl, pH 8.8, 500 mM KCl, 15 mM
MgCl2, 30 mM dithiothreitol, 1 mg mL21 BSA), 1 mL of 10 mM
dNTPs, 1 mL of each primer (10 mM), 0.5 mL of Taq DNA
polymerase (Roche), 500 ng of cDNA template, and deionized
distilled H2O (ddH2O) to a total volume of 50 mL. All PCR
products were analyzed by electrophoresis on 1.5% agarose gels.
Western Blot Analysis and Generation of Monoclonal
Antibody Against HKII
Cells were lysed using the following lysis buffer: 50 mM Tris
(pH 8.0), 110 mM NaCl, 5 mM EDTA, 1% Triton X-100, PMSF
(100 mg/mL), 10% glycerol, 1.5 mM MgCl2, and protease inhib-
itor cocktail (Roche). Protein concentrations were determined
using the BCA assay (Pierce). Whole-cell lysates containing 40–
80 mg of protein were boiled in equal volumes of loading buffer
(125 mM Tris–Cl, pH 6.8, 4% SDS, 20% glycerol, and 10% 2-
b-mercaptoethanol). Proteins were separated electrophoretically
on 7.5%210% denaturing polyacrylamide gels and subsequently
transferred to Hybond enhanced chemiluminescence (ECL) nitro-
cellulose membranes (Amersham) using the BioRad Mini-Gel
system. For immunoblotting, membranes were blocked with 5%
nonfat dried milk in Tris-buffered saline (TBS) for 1 h. The
primary antibody, HKII (Chemicon), and our own generated
antibody were applied at a 1:1,000 dilution for 1 h. And each
specific primary antibody was applied at 1:2,000–1:5,000 dilution
for 1 h. After washing twice with TBS containing 0.05% poly-
sorbate 20 (TTBS), secondary antibody (peroxidase-conjugated;
Zymed) was applied at a 1:5,000–1: 10,000 dilution for 1 h. Blots
were washed twice in TTBS for 10 min, incubated in commercial
ECL reagents (Pierce), and exposed to photographic film.
Because monoclonal antibody against human HKII is not
commercially available, we generated an anti-HKII antibody that
was produced from a mouse monoclonal antibody in our labora-
tory. Purified rhHKII protein was used to immunize BALB/c mice,
and hybridomas were generated and cloned as previously de-
scribed (19). A polyclonal antibody against HKI, Akt, p-Akt,
PI3K, and phosphorylated adenosine monophosphate–activated
protein kinase (p-AMPK) were purchased from Cell Signaling
Technology. Antibodies against HKIII, Glut-1, Glut-2, and G-6-
Pase were purchased from Santa Cruz Biotechnology. All appro-
priate secondary antibodies (conjugated to horseradish peroxidase)
were purchased from Zymed.
Cell Growth and Viability in SNU449 Cell Lines Before
and After Cisplatin Treatment
Cell growth in vitro was determined using cell growth curve
and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) assay. For cell growth curve, cells were harvested by
trypsinization, and the number of cells was counted. The effect of
cisplatin on the viability of cells was determined by MTT assay.
Cells were plated at 1 · 104 cells per well in 200 mL of RPMI
FIGURE 1. Expression profile of HKII in established stable
cells. Expression of HKII is significantly increased after
transfection in both SNU449 human HCC cell line and
control Chang cells. HepG2 cell line was used as positive
control for HKII. b-actin was used as loading controls for
Western blot analysis. SNU449-HKII 5 stable cells after
transfection of HKII; Chang-HKII 5 stable cells after trans-
fection of HKII.
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1640 complete medium containing various concentrations of
cisplatin in a 96-well microtiter plate. A 10-mg concentration of
cisplatin was repeated in 10 wells. After incubation for 24–72 h at
37C in a humidified incubator, cell viability was determined
using the MTT assay. Briefly, 4 mL of MTT reagent (5 mg/mL in
PBS) was added to each well and incubated for 2 h, and the plate
was centrifuged at 1,800 rpm for 5 min at 4C. The MTT solution
was removed from the wells by aspiration. Formazan crystals were
dissolved in 150 mL of dimethyl sulfoxide, and absorbance was
recorded on a microplate reader at a 540-nm wavelength.
Determination of Cellular ATP Content and Lactate
Production in SNU449 Cell Lines Before and
After Transfection
ATP was determined using the CellTiter-Glo luminescent cell
viability assay (Promega) based on ATP bioluminescence as a
marker of cell viability. The luminescence produced by the
luciferase-catalyzed luciferin plus ATP reaction was detected
using a MicroLumat LB96P multiwell scanning spectrophotome-
ter (EG&G Berthold; Bad). The data were normalized to the
control group.
Lactate was determined using a lactate assay kit (BioVision)
and following the manufacturer’s instructions. The absorbance
was recorded on a microplate reader at a 570-nm wavelength. The
data were normalized to the control group.
Evaluation of HKII in Cytosol and Mitochondria-Enriched
Fractions Before and After Treatment with PI3K Inhibitor
Cells were plated in 25-cm2 flasks and used at a final density of
1.5 · 106 cells per flask. After 24 h, cells were treated with
LY294002 (50 mM) for 1 h at 37C. After treatment, cells were
harvested by trypsinization and centrifuged at 600g for 10 min at
4C. The cell pellets were washed once in PBS and then
resuspended in 3 volumes of isolation buffer (20 mM HEPES,
pH 7.4, 10 mM KCl, 1.5 mM MgCl2, 1 mM sodium EDTA, 1 mM
dithiothreitol, 10 mM phenylmethylsulfonyl fluoride, 10 mM
leupeptin, and 10 mM aprotinin) in 250 mM sucrose. After
chilling on ice for 3 min, cells were disrupted by 60 strokes of
a glass homogenizer. The homogenate was centrifuged twice at
1,500g at 4C to remove unbroken cells and nuclei. The mito-
chondria-enriched fraction (heavy membrane fraction) was then
collected by centrifugation at 12,000g for 30 min. The supernatant
was removed and filtered through 0.2- and then 0.1-mm Ultrafree
MC filters (Millipore) to give cytosolic protein.
RESULTS
Expression Profiles of Hexokinase Isozymes, GLUTs,
and VDAC After HKII Transfection
We investigated whether HKII overexpression affects the
expression of other glycolytic enzymes such as HKI, HKIII,
and G6Pase and facilitated Glut-1 and Glut-2.
There was no significant alteration of gene expression of
these enzymes or transporters. Expression of VDAC, which
is important for mitochondrial association of hexokinases,
was also not changed (Supplemental Fig. 2). 18F-FDG
uptake was significantly increased after transfection in both
SNU449 and control Chang cells, approximately 52% and
40%, respectively (Fig. 2; Supplemental Fig. 3). On con-
focal microscopy, transfected cells, compared with non-
transfected cells, show significantly increased HKII protein
in the cells, and a large proportion of the HKII protein was
mitochondrially associated (Fig. 3).
FIGURE 2. Measurement of 18F-FDG uptake levels in
established stable cells. 18F-FDG PET images after trans-
fection of HKII show significantly increased 18F-FDG uptake
in both SNU449 and Chang cells by approximately 52% and
40%, respectively.
FIGURE 3. Subcellular localization of
HKII in SNU449 and SNU449-HKII cells.
Confocal microscopy shows markedly
increased HKII expression after trans-
fection (SNU449-HKII), and large pro-
portion of HKIIs are mitochondrially
associated. (A–C) SNU449 cells. (D–F)
SNU449 cells after transfection of HKII.
HKII protein is shown in A and D (red);
mitochondria are shown in B and E
(green); and HKII colocalized with mito-
chondria is shown in C and F (yellow-
orange).
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Cell Growth and Survival After Overexpression of HKII
HKII-transfected SNU449 cells showed a higher prolif-
eration rate, approximately 1.5- to 2- fold higher, than
nontransfected SNU449 cells (Fig. 4A). In control Chang
cells, there was no significant cellular proliferation after
transfection (data not shown).
When we treated the cell lines with the anticancer agent
cisplatin, HKII-transfected SNU449 cells showed poorer
response than did the control nontransfected SNU449 cells.
The data showed no change on day 1, but on days 2 and 3
there was a 2- and 8-fold higher cell survival after cisplatin
treatment, respectively, in HKII-transfected SNU449 cells
(Fig. 4B).
Molecular Mechanisms of Overexpressed HKII
Related to Cellular Proliferation and Resistance to
Anticancer Agent
HKII-transfected SNU449 cells, compared with non-
transfected cells, showed increased ATP (20%) and lactate
(45%) production but decreased phosphorylated AMPK
(Fig. 5; Supplemental Fig. 4). Because activated Akt is
known to play an important role in translocation of cyto-
plasmic hexokinases to the mitochondrial outer membrane
(20), we measured Akt after transfection. Total amount of
Akt was not different between transfected and nontrans-
fected SNU449 cells; however, the activated form (phos-
phorylated Akt, p-Akt) was significantly increased after
transfection. Treatment of PI3K inhibitor LY294002 (50
mM) induced reduction of p-Akt level (Fig. 6). In addition,
mitochondrial HKII fraction was decreased, but cytoplas-
mic HKII was increased (Fig. 7). Therefore, our results
suggest that the Akt signaling pathway is an important
regulating mechanism for tumor progression and poor
response to anticancer treatment; it is dependent on both
the PI3K and the AMPK pathways because increased
energy production (ATP) by overexpressed HKII could
activate Akt alternatively by means of AMPK inactivation.
DISCUSSION
Several previous studies using 18F-FDG PET have dem-
onstrated that tumors with high 18F-FDG uptake, compared
with low-uptake tumors, including HCC, have poor prog-
FIGURE 5. Effects of overexpressed HKII on AMPK phos-
phorylation. Activated form of AMPK (p-AMPK) is signifi-
cantly decreased after HK II transfection (SNU449-HKII).
Oligomycin (0.5 mM, 30 min) served as positive control of
p-AMPK because it is AMPK activator.
FIGURE 4. Effects of overexpressed
HKII on cell growth and anticancer treat-
ment response. Cellular proliferation is
significantly increased after HKII trans-
fection, approximately 1.5- to 2-fold,
compared with nontransfected cells (A).
After treatment with cisplatin (10 mg/mL)
for 3 d at 37C, there was 2- and 8-fold
increase in cell survival 2 and 3 d after
treatment, respectively (B). All measure-
ments were performed in triplicate; error
bars indicate SEM. Comparisons were
subjected to Student t test. A.U. 5
arbitrary unit. *P , 0.05. **P, 0.01.
FIGURE 6. Effects of PI3K inhibitor treatment. Activated
form of Akt (p-Akt) was significantly increased after HKII
transfection (SNU449-HKII), compared with control cells
without transfection (SNU449). After treatment with 50 mM
PI3K inhibitor LY294002 for 1 h, p-Akt level significantly
decreased. b-actin served as loading control.
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nosis (21,22). As 18F-FDG uptake in the tumor cells is
mostly dependent on membrane-bound Glut and hexoki-
nase expression levels (4,23) and 18F-FDG26-phosphate
does not undergo further glycolytic pathways (24), either
Glut or hexokinase expression might be related to tumor
progression on the premise that 18F-FDG uptake is corre-
lated with tumor aggressiveness. However, 18F-FDG uptake
appears to be more correlated with phosphorylating activity
of the mitochondria-bound hexokinases rather than Glut-1
(25). In fact, high-grade HCCs showed low incidence of
Glut-1 but increased HKII expression (5,17,18). Therefore,
hexokinase expression might play an important role in both
18F-FDG uptake and tumor progression in HCC.
Most malignant cells express hexokinase, mostly HKII,
up to 100 times higher than normal cells (26), and
50%280% of HKIIs are bound to the outer membrane of
mitochondria (7). Previous studies have demonstrated that
hexokinases bound to the outer membrane of mitochondria
produce an antiapoptotic activity (16,27), which is strongly
correlated with proliferation activity of malignant tumors
(7). Therefore, we evaluated whether overexpressed HKII
increases 18F-FDG uptake and how it may affect cellular
growth and proliferation. HKII overexpression was induced
in the SNU449 cell line that expressed low levels of HKII.
We confirmed through our established cell line that over-
expression of HKII produced increased 18F-FDG uptake
and the HKII protein was mitochondrially associated on
confocal microscopy; however, any other molecules that
are related to gluconeogenesis and glycolysis were not
changed (Supplemental Fig. 2). Thus, our cell line is an
ideal model for the evaluation of the role of HKII as an
increased 18F-FDG uptake mechanism and tumor progres-
sion.
There are several mechanisms of hexokinase overexpres-
sion in malignant cells. In particular, it has been demon-
strated that a short segment of the proximal region of HKII
promotor contains functionally active response elements for
c-Myc, hypoxia-inducible factor-1 (HIF-1), ras, and the
tumor suppressor p53 with point mutations (28). These
oncogenic alterations and related molecular pathways in
malignant cells affect tumor aggressiveness independently.
Additionally, these transcription factors also induce over-
expression of HKII in the malignant cells and effect higher
cellular proliferation and poor response to the anticancer
treatment. Overexpression of HKII resulted in more cellular
proliferation by up to 2-fold and caused poorer response to
anticancer treatment by 2- to 8-fold, compared with non-
transfected cells (Fig. 4).
The antiapoptotic mechanisms of the mitochondria-
bound form HKII have been extensively investigated. HKII
can directly bind to the mitochondrial outer membrane
protein, known as VDAC (7). VDAC is the pore in the
mitochondrial outer membrane through which all solutes
including ATP are transported. Mitochondrial ATP is
exported through the mitochondrial inner membrane by
the ANT. Consequently, the HKII-VDAC-ANT binding
interaction is crucial for energy supply as a form of ATP
to the phosphorylation reaction and for enhancing tumor
growth and cancer cell proliferation. HKII-VDAC-ANT
complex also inhibits Bax or Bak binding to the mitochon-
dria, and it prevents cytochrome c release, thereby inhibit-
ing tumor cell apoptosis (16,27).
These antiapoptotic effects of HKII are known to be
mediated by the PI3K downstream molecule Akt (27). Akt
mediates the signals of a variety of oncogenes or transcrip-
tional factors for tumor progression (29). In this study, the
active form of Akt (i.e., p-Akt) level was increased in
SNU449-HKII cells, although PI3K or growth factor re-
ceptor in upstream level was not stimulated. Usually PI3K
is activated by a large number of the plasma membrane
growth factor receptors, particularly receptors with tyrosine
kinase activity. PI3K is involved in the catalytic conversion
of phosphatidylinositol-3,4-bisphosphate to phosphatidyl-
inositol-3,4,5-trisphosphate (29). Activated PI3K recruits
Akt and PDK1 (phosphoinositide-dependent kinase 1) to
the plasma membrane. Akt is then activated by PDK1 and
phosphorylates multiple proteins on serine and threonine
residues (30).
PI3K/Akt signaling is important for the regulation of
transcription, migration, angiogenesis, cell growth, prolif-
eration, apoptosis, and glucose metabolism (31). In glucose
metabolism, PI3K/Akt signaling is important for the trans-
location of cytosolic HKII to the outer membrane of the
mitochondria for antiapoptotic activity as described earlier.
FIGURE 7. Translocation of HK II from
mitochondria to cytoplasm after treat-
ment with PI3K inhibitor. Total amount
of HKII protein was not changed after
treatment with 50 mM PI3K inhibitor
LY294002 for 1 h (A). HKII is expressed
more in mitochondrial fraction before
treatment. After treatment with PI3K
inhibitor, mitochondrial fraction de-
creased whereas cytosolic fraction in-
creased (B). b-actin and Hsp 60 served
as loading controls. Cyt 5 cytoplasmic
fraction X; Mt 5 mitochondria.
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Our results show that HKII dissociated from the mitochon-
dria and liberated into the cytoplasm after treatment with a
PI3K inhibitor LY294002 and support these mechanisms.
However, several reports have suggested that Akt could
be activated in a PI3K-independent manner (32). Among
them, AMPK—which plays a key role in the main regula-
tion of cellular energy homeostasis—is known to be an
important regulator of PI3K-independent Akt activation
(33). Activated AMPK can inhibit mammalian target of
rapamycin (mTOR), which is a downstream molecule of
Akt, but inactivation of AMPK produces Akt activation
alternatively (34,35). Conditions that activate AMPK are
glucose deprivation, hypoxia, ischemia, and heat shock, all
of which are associated with depleted cellular ATP, elevated
AMP levels, and an increased AMP-to-ATP ratio (34).
Therefore, AMPK is activated under nutrient-poor condi-
tions and inactive under nutrient-rich conditions (35). In
our study, HKII-overexpressed SNU449 cells showed
higher lactate production and ATP content and decreased
p-AMPK level (Fig. 5; Supplemental Fig. 4). Based on
these facts, Akt could be activated by an alternative PI3K-
independent AMPK signaling pathway in HKII overex-
pressed SNU449 cells, although growth factor receptor or
PI3K stimulation was not induced.
The mTOR is an important central downstream molecule
in both PI3K/Akt and AMPK pathways. This activates HIF-
1 (36) and activates HKII DNA promoter. It could be
another mechanism for further increasing HKII levels in
malignant cells (28), and vicious cycles ensue. In addition
to the antiapoptotic role of overexpressed HKII by means of
activated Akt, Akt itself has important functions as a
critical regulator of cell survival and proliferation. Balsara
et al. reported that Akt activation might have a role in the
conversion from a benign to a malignant tumor (37). In
addition, overexpression and mutation of Akt has been
observed in various cancers (38). Furthermore, activated
Akt accelerates tumor progression and promotes the ma-
lignant conversion of immortalized keratinocyte cell lines
(39). These molecular mechanisms are summarized in
Supplemental Figure 5.
CONCLUSION
Increased 18F-FDG uptake in HCC reflects HKII over-
expression; overexpressed HKIIs induce antiapoptotic ac-
tivity with higher cellular proliferation and poor response to
anticancer treatment through both the PI3K-dependent and
the independent Akt signal pathways. Therefore, 18F-FDG
PET can be a surrogate marker of prognosis in HCC.
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